Influence of ribavirin on the dynamics of hepatitis C viremia in interferon-α-treated patients with response or nonresponse;Einfluss von ribavirin auf die dynamik der hepatitis-C-viramie bei interferon-α-behandelten patienten mit response oder nonresponse

Zeitschrift fur Gastroenterologie

Volumn 38, Issue 11, 2000, Pages 881-886

  Berg, T ^a   Kaul, T ^a   Naumann, U ^a   Wiedenmann, B ^a   Hopf, U ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Antiviral Therapy; HCV; Quasispecies Distribution; Virus Kinetics

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIREMIA; VIRUS RESISTANCE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 0033667057     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-10299     Document Type: Article

References (36)

1. Randomized trial of interferon (2b plus ribavirin for 48 weeks or 24 weeks versus interferon (2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Molecular mechanisms of action of ribavirin
4. Broad spectrum activity of virazole: 1-beta-D-ribofuranosyl-1,2,3-triazole-3-carboxamide
5. Ribavirin treatment for chronic hepatitis C
6. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa
7. Ribavirin inhibits viral induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
8. Quasispecies in viral persistence and pathogenesis of hepatitis C virus
9. Efficacy of short-term Ribavirin plus interferon alfa combination therapy followed by interferon alone in previously untreated patients with chronic hepatitis C
10. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
11. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A non-B hepatitis
12. PCR-SSCP: Nonradioactive detection with biotinprimers and streptavidine-alkaline phosphatase conjugates
13. Non-isotopic detection of hepatitis C virus quasispecies by single strand conformation polymorphism
14. Hepatitis C viral dynamics and the antiviral efficacy of interferon-α therapy
15. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
16. Dose-dependent acute clearance of hepatitis genotype 1 virus with interferon alfa
17. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogeic factors in primary human and rat hepatocytes
18. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in ribavirin-treated patients using a high performance liquid chromatography linked method
19. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
20. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and nonresponders: Italian experience
21. Interferon-ribavirin combination therapy for chronic hepatitis C
22. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who failed to respond to achieve a sustained response to interferon alone: Swedish experience
23. Retreatment wit interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C
24. A pilot study of ribavirin and interferon beta for the retreatment of chronic hepatitis C
25. Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial
26. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
27. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferonalpha course: Results of a randomized multicenter trial
28. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy
29. Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? An analysis of personal experiences and review of the literature
30. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution
31. Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis
32. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy
33. Evolution of hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
34. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C
35. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus
36. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-α and ribavirin therapy